Brainsway Ltd. (BWAY) reports Q1 2026 earnings with 35% revenue growth to $15.5M and strong strategic initiatives in mental health treatments.

Key Takeaways

• Revenue increased by 35% year-over-year to $15.5 million for Q1 2026, compared to $11.5 million in Q1 2025.
• Net income surged over 100% to $2.3 million, up from $1.1 million in the prior year.
• The company achieved its 11th consecutive quarter of profitability with adjusted EBITDA rising 119% to $2.8 million.
• Remaining performance obligations (RPO) increased 25% year-over-year to $75 million, indicating strong future revenue potential.
• The company placed 117 Deep TMS systems during the quarter, bringing the total install base to approximately 1,820 systems.

Financial Performance

Brainsway Ltd. reported a robust financial performance for the first quarter of 2026, showcasing the strength of its business model and market strategy. The company achieved a 35% increase in revenue, totaling $15.5 million, compared to $11.5 million in the same quarter of the previous year. This growth reflects the successful execution of its core business and expanded market penetration.

Net income also saw a remarkable increase, more than doubling to $2.3 million, which translates into earnings per share (EPS) of roughly $0.16. Adjusted EBITDA reached $2.8 million, marking an impressive 119% growth from $1.3 million in Q1 2025. The company’s gross profit for the quarter was $11.6 million, maintaining a healthy gross margin, reflecting the efficiency of its operations.

Operating income was approximately $2 million, compared to $0.6 million reported for the same quarter last year. This improvement underscores the effectiveness of the company's recurring revenue model, which has been pivotal in enhancing cash flow and profitability.

Strategic Initiatives

Beyond its impressive financial metrics, Brainsway is making significant strides in strategic initiatives aimed at expanding its market presence and enhancing patient access to its innovative treatments. A key driver of this growth is the company's Deep Transcranial Magnetic Stimulation (Deep TMS) platform, which has gained traction due to its extensive peer-reviewed clinical evidence supporting its efficacy across multiple mental health conditions.

In Q1 2026, Brainsway shipped 117 Deep TMS systems, a 44% increase from the previous year, reflecting strong demand for its technology. Moreover, the company reported that the majority of new contracts signed were multi-year agreements, indicating robust long-term demand.

The strategic focus on expanding reimbursement coverage for Deep TMS treatment has also been a significant factor in driving growth. The company has successfully worked with major payers, including Evernorth Behavioral Health, to eliminate prior authorization requirements for TMS, thereby improving access for patients.

Furthermore, Brainsway has entered into strategic equity agreements with several mental health providers, enhancing its operational capabilities and market reach. Notably, the company signed a $1.5 million investment deal with HopeMark, a mental health provider in Illinois, and plans to invest further in its minority stake in these networks.

Future Outlook

Looking ahead, Brainsway maintains a positive outlook for Q2 and the remainder of 2026. The company expects to generate revenue between $66 million and $68 million, representing a year-over-year growth rate of 27% to 30%. Additionally, management anticipates adjusted EBITDA to reach between $12 million and $14 million, which would mark an expected growth of 86% to 100% compared to 2025.

The anticipated approval of Deep TMS for treating PTSD in patients with major depressive disorder is another important milestone. Management plans to submit an application to the FDA in the upcoming weeks, with expectations for approval by the end of the year. The success of this initiative could significantly expand the company's market potential.

Moreover, the company is seeing increasing interest in its SWIFT protocol, a new treatment regimen that reduces the duration of therapy, showing an 88% response rate within just six days. The growing acceptance of this protocol among providers and payers alike could further drive revenue growth.

Conclusion

In summary, Brainsway Ltd. has demonstrated strong financial performance in Q1 2026, with significant increases in revenue, net income, and operational efficiency. The company’s strategic initiatives, including expanding its product offerings and reimbursement coverage, position it well for continued growth in the mental health space. With a robust pipeline of upcoming treatments and a solid financial foundation, Brainsway is poised for a successful year ahead.

This analysis is based on public earnings call materials and is not investment advice.